BACKGROUND: This study was designed to evaluate the comparison of insertion of levonorgestrel (LNG)-releasing intrauterine system versus oral @entity11796 on @entity1869 in a randomized controlled trial. MATERIALS AND METHODS: A total of 60 @entity1 with the initial histopathological diagnosis of @entity1869 in two groups received LNG or @entity7839 (10 mg/d orally) for 12 days a month for 3 months). Endometrial biopsy was obtained for all @entity1 after 3 months of treatment. Response to treatment was defined based on the histopathology of the post treatment pipelle endometrial specimens in three categories of resolution, persistence and progression. RESULTS: Treatment response rate in @entity1 in the LNG group was 89.3% (25 of 28 @entity1 ), versus 70.4% (19 of 27 @entity1 ) in @entity1 in the @entity7839 group. The rate of persistence was 10.7% (3 of 28 @entity1 ) and 22.2% (6 of 27 @entity1 ) in LNG and @entity7839 groups respectively. No progression of @entity1869 observed in any of the @entity1 in LNG group, but progression of @entity1869 was observed in 7.4% (2 of 27 @entity1 ) in the @entity7839 group. There was no statistically significant difference between groups regarding the response to treatment (P = 0.15). Side effects such as bloating, @entity1017 , @entity1295 and hair loss were comparable between the groups (P > 0.05). Hirsutism was significantly more in the @entity7839 group than LNG group (P = 0.013). CONCLUSION: Results showed that the use of LNG for treating @entity1869 for 3 months was associated with high-treatment response rate and the low proportion of @entity1 with progression compared to the use of @entity7839 .

Levonorgestrel-releasing intrauterine system (Mirena) in compare to XXXX as a therapy for @entity1869 .

@entity1 :: ('9606', 'Species') :: ['women', 'patients'] @entity11796 :: ('MESH:D017258', 'Chemical') :: ['medroxyprogesterone acetate'] @entity7839 :: ('MESH:D008525', 'Chemical') :: ['medroxyprogesterone'] @entity1295 :: ('MESH:D005221', 'Disease') :: ['fatigue'] @entity1017 :: ('MESH:D015430', 'Disease') :: ['weight gain'] @entity1869 :: ('MESH:D004714', 'Disease') :: ['endometrial hyperplasia']
@entity11796 :: (MESH:D017258,Chemical) :: ['medroxyprogesterone acetate']
